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Abstract 
Background: Diabetes mellitus (DM) and aortic stenosis (AS) are frequent findings in the elderly population. Data 
regarding the influence of DM on the outcomes of patients undergoing transcatheter aortic valve replacement (TAVR) 
due to AS are limited. The aim of this study was to examine the impact of DM on TAVR outcomes.
Methods: We investigated 443 patients with severe AS undergoing TAVR. Subjects were divided into insulin-depend-
ent diabetic mellitus (IDDM) patients (N = 44), non-dependent insulin diabetic mellitus (NIDDM) patients (N = 114) 
and non-diabetics (N = 285) of whom 31 (74 %), 86 (79 %) and 209 (76 %) respectively had trans-femoral TAVR. Peri-
procedural complications and outcomes were recorded according to the Valve Academic Research Consortium-2 
criteria.
Results: Patients with IDDM as well as NIDDM demonstrated similar complication rates compared with non-diabetic 
patients, except for acute kidney injury (AKI) grade 3 [4 (2 %) and 3 (3 %) vs. 1 (0.4 %) respectively, p = 0.032]. Kaplan–
Meier survival analysis showed that DM, regardless of the type of treatment, was not associated with increased 2 years 
mortality (Log-rank p value 0.44). Multivariate cox regression analysis adjusted for age, gender, coronary artery disease, 
DM, AKI3, hypertension, chronic renal failure and peripheral vascular disease found that AKI3 was associated with 
increased risk of 2 years mortality [HR = 7.35, 95 % CI 2.16–25.07, p = 0.001] whereas female gender was found as a 
protective factor [HR = 0.47, 95 % CI 0.28–0.8, p = 0.005], and DM was not associated with increased risk.
Conclusions: Following TAVR, DM patients seem to have similar peri-procedural and mid-term outcomes compared 
with patients without DM, while IDDM patients seem to suffer greater incidence of AKI. Further research in larger 
cohorts of patients is needed to validate our results.
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Background
Trans-catheter aortic valve replacement (TAVR), pre-
viously reserved for surgically high-risk patients with 
symptomatic aortic stenosis (AS), is now being utilized 
in a wider range of patients [1, 2]. Patients treated with 
TAVR have shown significant alleviation of symptoms 
and improved functional status [3, 4].
Diabetes mellitus (DM) and AS are both prevalent in 
the elderly population, and symptomatic AS has been 
found to be associated with DM [5]. Following cardiac 
surgery, patients with DM have been shown to suffer 
higher rates of renal dysfunction, need for blood transfu-
sions and lung complications. Furthermore, DM patients 
undergoing TAVR have been shown to have less com-
plications than DM patients undergoing surgical aor-
tic valve replacement (SAVR) [6], and while mortality 
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rates in patients undergoing TAVR have been shown to 
be equivalent [7] or reduced [8] compared with patients 
treated with SAVR, little is known about the impact 
of DM on the clinical outcomes of patients undergo-
ing TAVR compared with the non-DM population. The 
aim of the current study was to investigate the clinical 
outcomes and complication rates among DM patients 
undergoing TAVR.
Methods
The study included 443 consecutive patients undergo-
ing TAVR at the Sheba Medical Center between January 
2008 and December 2014, of which 158 (36 %) had DM. 
We analyzed separately DM patients treated with insu-
lin (IDDM) (44 [28  %]) and those treated either by diet 
or oral anti-diabetic agents (114 [72 %]). Candidates for 
TAVI were evaluated separately by an interventional car-
diologist and by a cardiac surgeon. Cases were then dis-
cussed by the heart team which convenes on a weekly 
basis. Final decision to advise TAVR vs. SAVR was made 
by the heart team based on suitability for TAVI and surgi-
cal risk.
Baseline clinical data and chronic medication use were 
obtained from patients’ electronic records. Patients with 
impaired renal function (creatinine >1.2 mg/dl) received 
peri-procedural balanced intravenous volume expansion 
with isotonic sodium chloride [9]. Peri-procedural com-
plications were prospectively recorded according to the 
Valve Academic Research Consortium (VARC)-2 criteria. 
Mortality rates were ascertained with the Israeli Ministry 
of Interior mortality database through January 2015.
The study was approved by the local institutional review 
board (clinicaltrial.gov: SHEBA-13-0685-IB-CTIL).
Definitions and outcome measures
Patients were considered to have DM if they fulfilled at 
least one of the followings: (1) HbA1c >6.5 % at admis-
sion, (2) a random plasma glucose level higher than 
200  mg/dl in the presence of symptoms, (3) use of glu-
cose lowering medications. All DM patients had type 2 
DM. Renal dysfunction was defined as a serum creatinine 
level greater than 1.4 mg %.
The primary outcome of the current study was all 
cause mortality during a follow-up period of 2  years. 
Median follow-up time for the entire study population 
was 599  days. Secondary outcomes were defined as any 
VARC-2 defined peri-procedural complication.
Statistical analysis
Continuous data were compared with Student’s t-test and 
one-way ANOVA. Categorical data were compared with 
the use of Pearson Chi square test.
Table 1 Baseline characteristics
All values are expressed as mean ± SD or N (%)
NIDDM non-insulin dependent diabetes mellitus, IDDM insulin dependent diabetes mellitus, CHF congestive heart failure, NYHA New York Heart Association, COPD 
chronic obstructive lung disease, CABG coronary artery bypass surgery, PCI percutaneous coronary intervention, STS Society of Thoracic Surgeons
Non-diabetic (N = 285) Diabetic (N = 158) P-value
NIDDM (N = 114) IDDM (N = 44)
Age 81.8 ± 7.5 79.8 ± 7.5 79.4 ± 7.7 0.016
Male 128 (46) 53 (46) 23 (52) 0.71
Hemoglobin 11.5 (1.4) 11.6 (1.4) 12.6 (2.2) 0.18
Glucose 91 (13) 97 (21) 95 (34) 0.21
Renal dysfunction 46 (17) 21 (20) 23 (59) <0.001
Hypertension 232 (84) 103 (94) 34 (83) 0.032
Dyslipidemia 199 (72) 90 (83) 34 (85) 0.036
Coronary artery disease 124 (46) 48 (45) 24 (60) 0.22
CHF-NYHA class III–IV 165 (58) 62 (54) 23 (52) 0.64
Atrial fibrillation/flutter 66 (27) 29 (28) 13 (33) 0.71
Peripheral vascular disease 33 (12) 13 (12) 6 (15) 0.85
Current smoker 11 (4) 2 (2) 2 (5) 0.53
COPD 41 (15) 19 (18) 11 (28) 0.13
s/p CABG 57 (21) 22 (21) 10 (26) 0.8
s/p PCI 73 (27) 30 (29) 14 (36) 0.55
Pacemaker 21 (8) 7 (7) 2 (5) 0.79
STS mortality 5.3 ± 3.7 5.2 ± 2.9 7.6 ± 5.6 0.21
EUROSCORE 2 4.9 ± 5.1 4.7 ± 5.3 9.1 ± 8.7 0.16
HbA1c 5.7 ± 0.43 6.8 ± 1.00 7.9 ± 1.47 <0.001
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Kaplan–Meier survival analysis was used to descrip-
tively show the association between DM and subsequent 
mortality. Multivariate cox regression adjusted for age, 
gender, coronary artery disease, DM, AKI3, hyperten-
sion, chronic renal failure and peripheral vascular disease 
was performed in order to find risk factors for mortal-
ity. Statistical significance was accepted for a two-sided 
p  <  0.05. The statistical analyses were performed with 
IBM SPSS version 20.0 (Chicago, IL, USA).
Results
Of 443 patients included in the study 158 (36  %) had 
DM. These patients were compared with the 285 (64 %) 
patients without DM. Of the 158 diabetic patients 44 
(28  %) were treated with insulin, while the others were 
treated either orally or by diet. Baseline clinical and 
laboratory characteristic by DM status are presented in 
Table  1. Notably, DM subjects were on average 2  years 
younger than non-diabetic patients and had a greater 
incidence of dyslipidemia. Subjects with IDDM had sig-
nificantly greater incidence of baseline renal dysfunction. 
However, no other major differences in baseline char-
acteristics were noted between groups, including STS 
score, EUROSCORE, NYHA class, or presence of coro-
nary artery disease.
Procedural characteristics are summarized in Table 2. In 
most patients TAVR was performed via the trans-femoral 
approach (76  %) using conscious sedation (63  %). There 
were no differences between groups regarding the vascular 
approach, type of anesthesia, valve type or valve size used.
Diabetic patients demonstrated similar complica-
tion rates compared with non-diabetic patients (Table 3, 
Fig.  1), except for acute kidney injury (AKI) grade 3, 
which was more common in the IDDM group [1 (0.4 %) 
vs. 3 (3  %) and 2 (4  %), for non-diabetic, NIDDM, and 
IDDM respectively, p = 0.032]. No other significant dif-
ferences were noted between groups.
The primary study outcome occurred in 108 (24.4  %) 
subjects. Kaplan–Meier survival analysis (Fig. 2) showed 
that the cumulative probability for mortality through 
2 years of follow-up was not different between the groups 
(p-value Log rank =  0.439), although there was a trend 
towards higher mortality among patients with IDDM.
Multivariate cox regression adjusted for age, gender, 
coronary artery disease, DM, AKI3, hypertension, chronic 
renal failure and peripheral vascular disease found that 
Table 2 Procedural characteristics of TAVR patients
All values expressed as N (%)
NIDDM non-insulin dependent diabetes mellitus, IDDM insulin dependent diabetes mellitus
Non-diabetic (N = 285) Diabetic (N = 158) P-value
NIDDM (N = 114) IDDM (N = 44)
Approach
 Trans-femoral 209 (76) 86 (79) 31 (74) 0.53
 Trans-apical 49 (18) 19 (17) 9 (21)
 Other 17 (6) 3 (3) 2 (5)
Anesthesia
 General 89 (39) 34 (34) 12 (36) 0.55
 Conscious sedation 140 (61) 66 (66) 21 (61)
Valve type
 SAPIEN XT 109 (41) 48 (45) 18 (45) 0.35
 CoreValve 159 (58) 55 (51) 20 (50)
 Other 5 (1) 2 (2) 0 (0)
Valve size
 23 mm 52 (20) 19 (18) 9 (24) 0.77
 25 mm 0 (0) 1 (1) 0 (0)
 26 mm 106 (41) 45 (44) 13 (35)
 29 mm 93 (36) 34 (33) 13 (35)
 31 mm 6 (2) 4 (4) 2 (5)
 Valve-in-valve 25 (9) 12 (11) 8 (20) 0.11
 Procedural success 262 (98) 103 (97) 38 (100) 0.59
 Pre procedural EF 55 ± 12 56 ± 12 54 ± 12 0.48
 Pre-procedural moderate to severe MR 74 (26) 26 (23) 10 (23) 0.76
 Post-procedural moderate to severe AR 37 (13) 14 (12) 2 (5) 0.27
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AKI3 [HR  =  7.35, 95  % CI 2.16–25.07, p  =  0.001] and 
peripheral vascular disease [HR  =  1.95, 95  % CI 1.12–
3.39, p  =  0.019] were associated with increased risk of 
2-year mortality. Female gender was found to be a protec-
tive factor [HR = 0.47, 95 % CI 0.28–0.8, p = 0.005] and 
DM was not associated with increased risk (Table 4).
Table 3 Cardiac complications
All values expressed as N (%)
NIDDM non-insulin dependent diabetes mellitus, IDDM insulin dependent diabetes mellitus, MI myocardial infarction, LBBB left bundle branch block, RBBB right 
bundle branch block, AF atrial fibrillation
Complication Non-diabetic (N = 285) Diabetic (N = 158) P-value
NIDDM (N = 114) IDDM (N = 44)
30-days mortality 12 (4.2) 3 (2.6) 2 (4.5) 0.73
6-months mortality 28 (9.8) 5 (4.4) 3 (6.8) 0.18
1-year mortality 39 (13.7) 11 (9.6) 4 (9.1) 0.43
Conversion to open surgery 5 (2) 0 (0) 0 (0) 0.24
Unplanned cardiopulmonary bypass 3 (1) 0 (0) 0 (0) 0.43
Coronary obstruction 1 (0.4) 1 (0.9) 0 (0) 0.7
Cardiac tamponade 8 (3) 4 (4) 1(2) 0.91
Valve malpositioning 11 (4) 7 (6) 1 (2) 0.5
Valve migration 11 (4) 5 (4) 1 (2) 0.83
Peri-procedural MI (≤72 h post procedure) 9 (3) 1(1) 1 (2) 0.41
Spontaneous MI (≤72 h post procedure) 3 (1) 0 (0) 1 (2) 0.36
Transient atrio-ventricular block 21 (9) 9 (9) 3 (7) 0.96
Permanent atrio-ventricular block 41 (17) 18 (18) 5 (12) 0.72
Permanent pacemaker implantation 55 (22) 24 (23) 8 (19) 0.86
New LBBB 78 (32) 30 (29) 8 (19) 0.27
New RBBB 3 (1) 1 (1) 0 (0) 0.77
New onset AF 27 (11) 17 (16) 3 (7) 0.22
AF episode in patient with history of AF 13 (5) 7 (7) 3 (7) 0.78
Heart failure post-procedure 23 (9) 12 (12) 7 (17) 0.33
Fig. 1 Systemic complication rates. The figure shows the systemic 
complication rates (in percentage) according to diabetic status
Fig. 2 Kaplan–Meier analysis for 2 years survival. The Kaplan–Meier 
analysis was used to compare the probability of 2 years survival 
according to diabetic status. P value (Log rank) = 0.439
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We performed two additional sub-group analyses: first 
we analyzed outcomes of diabetic patients based on their 
HbA1C levels. Documented HbA1C levels during hospi-
talization were available in 105 patients with DM. Out-
comes of well-controlled diabetic patients with HbA1C 
levels below 7 % were equivalent to diabetic patients with 
HbA1C levels equal to or above 7  % (Additional file  1: 
Table S1). While numerically higher 1 year mortality rates 
were noted among DM patients with HbA1c levels above 
7 % compared with those below 7 % [2 (4 %) vs 5 (9 %), 
p  =  0.23], this finding did not reach statistical signifi-
cance, probably due to the relatively small group sample.
Discussion
The major finding of our study is that DM patients 
undergoing TAVR seem to have favorable outcomes with 
similar short and mid-term mortality rates compared 
with non-DM patients. Patients with IDDM in our study 
had greater incidence of renal insufficiency at baseline 
and both DM groups suffered from increased rate of 
AKI after the procedure, however other peri-procedural 
complications occurred equally among DM and non-DM 
patients.
Up to 40  % of older individuals have DM [10]. Elderly 
DM patients have unique characteristics and suffer from 
higher cardiovascular disease rates compared to younger 
DM patients [11]. However, limited data exists with 
respect to the effect of DM on mortality after TAVR. Our 
findings are supported by two previous studies: Minha 
et al. [12] followed 499 patients who had TAVR and con-
cluded that DM was not associated with poor outcome. 
However in this study patients were not divided according 
to treatment type (insulin vs. oral hypoglycemic agents). 
Conrotto et  al. [13] examined 511 patients undergoing 
TAVR, of whom 150 had DM, and also found no difference 
regarding the short and mid-term effect of DM on mortal-
ity rates in these patients. A number of studies suggest dif-
ferential outcomes in DM patients: Tamburino et al. [14], 
in a study of 663 patients after TAVR found a higher inci-
dence of DM among those who died and argued that DM 
at baseline may be associated with increased mortality. 
However this study failed to compare baseline character-
istics between DM and non-DM subjects and is inherently 
biased in that it examined characteristics of patients who 
died following the procedure. Similarly, Puls et  al. [15] 
reported poor outcome among 108 DM patients. How-
ever, in contrast to our series, most TAVR were performed 
by the transapical approach and their total mortality rates 
were much higher than those found in our cohort, suggest-
ing that these patients had greater baseline risk.
While we failed to demonstrate statistically signifi-
cant differences in mortality rates between IDDM and 
NIDDM patients, Kaplan–Meier analysis did suggest a 
trend towards worse outcomes among IDDM subjects. 
However, our sample size is inadequate to properly 
address mortality between groups.
Acute kidney injury rates were significantly higher 
among DM patients, especially the IDDM group. This 
finding is not surprising given the higher CRF rates at 
baseline. Previous studies have found CRF and AKI 
injury to be predictors for in-hospital mortality, 30 days 
mortality and 1 year mortality post-TAVR [16–19]. Our 
findings are similar to those mentioned above. However, 
and despite having higher rates of AKI, IDDM patients in 
our study did not demonstrate significantly higher mor-
tality rates when compared with NIDDM patients or with 
non-diabetic patients. A possible explanation for this 
discrepancy may be the small number of IDDM or the 
relatively small number of events (AKI) in the population 
which failed to reach statistical significance.
Limitations
This paper is based on a moderately sized cohort emanat-
ing from a single center. The limited number of enrolled 
patients does not allow assessment of specific outcome 
measures and sub-group analysis and avoids the potential 
for a propensity-matched evaluation or use of post hoc 
comparisons between the three groups due to high-risk 
for type II errors. Larger cohorts are necessary to further 
assess the prognostic impact of diabetes mellitus on out-
come after TAVR.
Conclusions
Diabetic patients seem to have favorable short- and mid-
term outcomes following TAVR which are similar to 
patients without DM. Insulin treated DM patients may 
have greater incidence of AKI, and appropriate peri-pro-
cedural strategies should be employed to minimize this 
risk in these patients.
Additional file
Additional file 1: Table S1. Complication rates based on HbA1c levels.
Table 4 Multivariate cox regression analysis for  2-year 
mortality
Analysis was further adjusted for age, coronary artery disease and hypertension
Factor HR 95 % confidence interval P value
Acute kidney injury 3 7.35 2.15–25.07 0.001
Peripheral vascular disease 1.95 1.12–3.39 0.019
Chronic renal failure 1.59 0.96–2.62 0.07
Diabetes mellitus 0.83 0.49–1.40 0.48
Female gender 0.47 0.28–0.80 0.005
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